Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma
Overview
Affiliations
Purpose: To identify prognostic factors and a model predictive for survival in patients with metastatic renal-cell carcinoma (RCC).
Patients And Methods: The relationship between pretreatment clinical features and survival was studied in 670 patients with advanced RCC treated in 24 Memorial Sloan-Kettering Cancer Center clinical trials between 1975 and 1996. Clinical features were first examined univariately. A stepwise modeling approach based on Cox proportional hazards regression was then used to form a multivariate model. The predictive performance of the model was internally validated through a two-step nonparametric bootstrapping process.
Results: The median survival time was 10 months (95% confidence interval [CI], 9 to 11 months). Fifty-seven of 670 patients remain alive, and the median follow-up time for survivors was 33 months. Pretreatment features associated with a shorter survival in the multivariate analysis were low Karnofsky performance status (<80%), high serum lactate dehydrogenase (> 1.5 times upper limit of normal), low hemoglobin (< lower limit of normal), high "corrected" serum calcium (> 10 mg/dL), and absence of prior nephrectomy. These were used as risk factors to categorize patients into three different groups. The median time to death in the 25% of patients with zero risk factors (favorable-risk) was 20 months. Fifty-three percent of the patients had one or two risk factors (intermediate-risk), and the median survival time in this group was 10 months. Patients with three or more risk factors (poor-risk), who comprised 22% of the patients, had a median survival time of 4 months.
Conclusions: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more. These risk categories can be used in clinical trial design and interpretation and in patient management. The low long-term survival rate emphasizes the priority of clinical investigation to identify more effective therapy.
Tomcova Z, Obertova J, Chovanec M, Sycova-Mila Z, Stefanikova K, Slachtova E Biomedicines. 2025; 13(2).
PMID: 40002897 PMC: 11852442. DOI: 10.3390/biomedicines13020484.
Pacholczak-Madej R, Drobniak A, Grela-Wojewoda A, Calik J, Viegas N, Tusien-Malecka D Clin Exp Med. 2025; 25(1):45.
PMID: 39849293 PMC: 11759459. DOI: 10.1007/s10238-024-01544-4.
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.
Basu A, Au C, Kommalapati A, Kandala H, Sudhaman S, Mahmood T JCO Precis Oncol. 2024; 8:e2400667.
PMID: 39693589 PMC: 11670910. DOI: 10.1200/PO-24-00667.
Urlic I, Soljic V, Vukoja M, Marijanovic I, Kraljevic M, Urlic M Int J Mol Sci. 2024; 25(22).
PMID: 39596188 PMC: 11594840. DOI: 10.3390/ijms252212120.
Figaroa O, Zondervan P, Kessels R, Berkhof J, Aarts M, Hamberg P Eur Urol Open Sci. 2024; 70:28-35.
PMID: 39483517 PMC: 11525453. DOI: 10.1016/j.euros.2024.09.002.